Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review

Li, Tiantian; Ao, Edwin C. I.; Lambert, Bieke; Brans, Boudewijn; Vandenberghe, Stefaan; Mok, Greta S. P.

doi:10.7150/thno.19782

Cited by 77 publications

(48 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite being in the era of precision medicine, which RIT conforms with, current protocols still implement a “one-dose-fits-all” approach. As the distribution of radiolabeled mAbs is variable among patients with AML, it is vital that the accuracy for individualized organ doses be improved by being able to monitor and adjust dosages [192]. The development of more precise and streamlined methods for individualized patient dosimetric determination will increase the effectiveness of RIT for R/R AML.…”

Section: Radioimmunotherapy Of Amlmentioning

confidence: 99%

Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats

Williams

Law

Hunyadkürti

et al. 2019

JCM

View full text Add to dashboard Cite

In recent decades, therapy for acute myeloid leukemia (AML) has remained relatively unchanged, with chemotherapy regimens primarily consisting of an induction regimen based on a daunorubicin and cytarabine backbone, followed by consolidation chemotherapy. Patients who are relapsed or refractory can be treated with allogeneic hematopoietic stem-cell transplantation with modest benefits to event-free and overall survival. Other modalities of immunotherapy include antibody therapies, which hold considerable promise and can be categorized into unconjugated classical antibodies, multivalent recombinant antibodies (bi-, tri- and quad-specific), toxin-conjugated antibodies and radio-conjugated antibodies. While unconjugated antibodies can facilitate Natural Killer (NK) cell antibody-dependent cell-mediated cytotoxicity (ADCC), bi- and tri-specific antibodies can engage either NK cells or T-cells to redirect cytotoxicity against AML targets in a highly efficient manner, similarly to classic ADCC. Finally, toxin-conjugated and radio-conjugated antibodies can increase the potency of antibody therapies. Several AML tumour-associated antigens are at the forefront of targeted therapy development, which include CD33, CD123, CD13, CLL-1 and CD38 and which may be present on both AML blasts and leukemic stem cells. This review focused on antibody therapies for AML, including pre-clinical studies of these agents and those that are either entering or have been tested in early phase clinical trials. Antibodies for checkpoint inhibition and microenvironment targeting in AML were excluded from this review.

show abstract

Section: Radioimmunotherapy Of Amlmentioning

confidence: 99%

Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats

Williams

Law

Hunyadkürti

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Another relevant aspect in theranostics is the use of quantitative imaging to provide patient-specific dosimetry to guide subsequent radionuclide therapy. Imaging dosimetry requirements are out of the scope of this review article, being the readers directed to recent articles on this key topic [25,26,27,28].…”

Section: Introductionmentioning

confidence: 99%

Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics

et al. 2018

View full text Add to dashboard Cite

Precision medicine relies on individually tailored therapeutic intervention taking into account individual variability. It is strongly dependent on the availability of target-specific drugs and/or imaging agents that recognize molecular targets and patient-specific disease mechanisms. The most sensitive molecular imaging modalities, Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), rely on the interaction between an imaging radioprobe and a target. Moreover, the use of target-specific molecular tools for both diagnostics and therapy, theranostic agents, represent an established methodology in nuclear medicine that is assuming an increasingly important role in precision medicine. The design of innovative imaging and/or theranostic agents is key for further accomplishments in the field. G-protein-coupled receptors (GPCRs), apart from being highly relevant drug targets, have also been largely exploited as molecular targets for non-invasive imaging and/or systemic radiotherapy of various diseases. Herein, we will discuss recent efforts towards the development of innovative imaging and/or theranostic agents targeting selected emergent GPCRs, namely the Frizzled receptor (FZD), Ghrelin receptor (GHSR-1a), G protein-coupled estrogen receptor (GPER), and Sphingosine-1-phosphate receptor (S1PR). The pharmacological and clinical relevance will be highlighted, giving particular attention to the studies on the synthesis and characterization of targeted molecular imaging agents, biological evaluation, and potential clinical applications in oncology and non-oncology diseases. Whenever relevant, supporting computational studies will be also discussed.

show abstract

“…15,16 For theranostic applications, activity late after injection is important for radiation dosimetry studies, but owing to limitations of current scanners, uptake after 2 to 3 half-lives is typically extrapolated and not measured. 17 Accurate delineation of the "tail" of radiotracer clearance could have a significant impact on estimates of dosimetry, especially important in applications of theranostic dosing. The increased sensitivity may also enable previously challenging clinical tasks.…”

Section: Measuring Kinetics Over a Prolonged Time Period After Injectionmentioning

confidence: 99%

Analysis of Four-Dimensional Data for Total Body PET Imaging

et al. 2021

View full text Add to dashboard Cite

Dynamic imaging on total-body PET scanners will allow us to image multiple organs and lesions simultaneously and select the most apt blood supply as an input function for each lesion. The high sensitivity of total-body PET will allow for short (100 ms) temporal frames and low dose (0.5-2 mCi) dynamic imaging. Using the high temporal sampling and high sensitivity of total-body PET, parametric images of the whole body can be generated, showing higher lesion contrast than traditional SUV images. 4D total-body PET can also be leveraged for 4D lesion heterogeneity analysis using machine learning, as well as dual tracer imaging with two 18F-labeled tracers.

show abstract

Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review

Cited by 77 publications

References 97 publications

Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats

Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats

Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics

Analysis of Four-Dimensional Data for Total Body PET Imaging

Contact Info

Product

Resources

About